Abstract | BACKGROUND: METHODS: To validate FAK as a TAA recognized by CD4 helper T lymphocytes (HTL), we have combined the use of predictive peptide/MHC class II binding algorithms with in vitro vaccination of CD4 T lymphocytes from healthy individuals and melanoma patients. RESULTS: Two synthetic peptides, FAK(143-157) and FAK(1,000-1,014), induced HTL responses that directly recognized FAK-expressing tumor cells and autologous dendritic cells pulsed with FAK-expressing tumor cell lysates in an HLA class II-restricted manner. Moreover, since the FAK peptides were recognized by melanoma patient's CD4 T cells, this is indicative that T cell precursors reactive with FAK already exist in peripheral blood of these patients. CONCLUSIONS: Our results provide evidence that FAK functions as a TAA and describe peptide epitopes that may be used for designing T cell-based immunotherapy for FAK-expressing cancers, which could be used in combination with newly developed FAK inhibitors.
|
Authors | Hiroya Kobayashi, Makoto Azumi, Yuka Kimura, Keisuke Sato, Naoko Aoki, Shoji Kimura, Masaru Honma, Hajime Iizuka, Masatoshi Tateno, Esteban Celis |
Journal | Cancer immunology, immunotherapy : CII
(Cancer Immunol Immunother)
Vol. 58
Issue 6
Pg. 931-40
(Jun 2009)
ISSN: 1432-0851 [Electronic] Germany |
PMID | 18941742
(Publication Type: Journal Article, Research Support, N.I.H., Extramural)
|
Chemical References |
- Antigens, Neoplasm
- Epitopes, T-Lymphocyte
- Peptide Fragments
- Focal Adhesion Protein-Tyrosine Kinases
|
Topics |
- Antigens, Neoplasm
(immunology)
- Blotting, Western
- CD4-Positive T-Lymphocytes
(immunology)
- Epitopes, T-Lymphocyte
(immunology)
- Focal Adhesion Protein-Tyrosine Kinases
(immunology)
- Genes, MHC Class II
(physiology)
- Humans
- Immunoenzyme Techniques
- Immunotherapy
- Melanoma
(therapy)
- Peptide Fragments
(immunology)
- T-Lymphocytes, Helper-Inducer
(immunology)
- Tumor Cells, Cultured
|